SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 3, 2002
IDEC PHARMACEUTICALS CORPORATION
(Exact name of
registrant as specified in its charter)
|
Delaware |
|
0-19311 |
|
33-0112644 |
|
|
(State or other
jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
|
|
3030 Callan Road, San Diego, CA |
|
|
92121 |
||
|
(Address of principal executive offices) |
|
|
(Zip Code) |
||
|
|
|||||
|
Registrant’s telephone number, including area code: (858) 431-8500 |
|||||
|
|
|||||
|
N/A |
|||||
|
(Former name or former address, if changed since last report) |
|||||
|
|
|||||
ITEM 5. Other Events.
Nabil Hanna, the company’s chief scientific officer, has informed us that he has established a non discretionary sales plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 in order to gradually diversify his holdings. The sales plan takes effect September 8, 2003 and expires December 31, 2004. The sales plan provides for sales of up to 150,000 shares per three month period depending on prevailing market prices. The maximum number of shares which can be sold under the sales plan is 313,600.
ITEM 7. Financial Statements and Exhibits.
(a)
Financial Statements
None.
(b)
Pro Forma Financial Statements
None.
(c)
Exhibits
None.
2
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 3, 2003
|
|
|
IDEC PHARMACEUTICALS CORPORATION |
|
|
|
|
|
|
|
|
|
By |
/s/ JOHN M. DUNN |
|
|
|
|
|
|
|
|
Name: |
John M. Dunn |
|
|
|
Title: |
Senior Vice President and General Counsel |
3